880 results on '"Lübbert, M"'
Search Results
2. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
3. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
4. Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020
5. Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial
6. Repeat to gene expression ratios in leukemic blast cells can stratify risk prediction in acute myeloid leukemia
7. Erratum zu: Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020
8. Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
9. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
10. 10-day decitabine versus 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3trial.
11. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
12. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
13. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
14. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
15. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
16. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS
17. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes
18. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
19. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
20. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
21. Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group
22. BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1)
23. P135 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
24. P134 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS
25. P095 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
26. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
27. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
28. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
29. Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS
30. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
31. Single-Center Retrospective Analysis of Prognosis of 138 Patients Older than 55 Years with Acute Myeloid Leukemia
32. Inducible AML1/ET0 Expression in U-937 Myeloid Cells: a Model to Identify Genes Targeted by the Leukemia-Specific Fusion Protein
33. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
34. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
35. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group
36. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
37. System Test Performance for the Ball Two-Stage Stirling-Cycle Cryocooler
38. P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY
39. P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS
40. S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
41. P328: DYNAMIC EVOLUTION OF TCF3-PBX1 LEUKEMIAS AT THE SINGLE-CELL LEVEL UNDER CHEMOTHERAPY PRESSURE
42. P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.
43. PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
44. P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA
45. DNA-Hypermethylierung als therapeutische Zielstruktur bei myelodysplastischen Syndromen
46. 10-Tage Decitabin vs. Standard-Induktion, mit nachfolgender allogener Stammzelltransplantation (HSZT) bei AML-Patienten ≥ 60 Jahre : eine randomisierte Phase III Intergroup-Studie der EORTC Leukemia Group, GIMEMA, CELG und GMDS-SG
47. Clonal Analysis of n-ras Gene Activation in Acute Myeloid Leukemia
48. Hematopoietins: New Tools in the Treatment of Hematopoietic Insufficiency
49. Myeloperoxidase: Gene Demethylation and Expression in Acute Myeloid Leukemias
50. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.